Clinical trial · no report yet · Phase 3
LungTIME-C01
Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC
- NCT05549037 ↗
- Completed
- Hunan Province Tumor Hospital
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 11 |
The trial
ClinicalTrials.gov- Official title
- Progression Survival Time According to Time-of-Day (ToD) of Administration of Immunochemotherapy for Advanced Non-small Cell Lung Cancer: A Phase III Randomized Control Trial
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Pembrolizumab, Sintilimab
- Arms
- Arm A: Morning group · Experimental
- Arm B: Afternoon group · Experimental
- Enrollment
- 210
- Primary outcomes
- Progression-free survival (PFS)
- Sponsor
- Hunan Province Tumor Hospital
- Start
- Sep 23, 2022
- Primary completion
- Dec 2, 2024
- Results posted
- No
- Registry record
- NCT05549037 · updated Jun 3, 2026
Publications
linked from the registry- Huang Z, Zeng L, Ruan Z, Zeng Q, Yan H, Jiang W, Xiong Y, Zhou C, Yang H, Liu L, Dai J, Zou N, Xu S, Wang Y, Wang Z, Deng J, Chen X, Wang J, Xiang H, Li X, Duchemann B, Chen G, Xia Y, Mok T, Scheiermann C, Levi F, Yang N, Zhang Y. Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial. Nat Med. 2026 Apr;32(4):1233-1240. doi: 10.1038/s41591-025-04181-w. Epub 2026 Feb 2. PubMed 41629425